US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Gastroesophageal Reflux · Migraine · ADXN
Addex Therapeutics
Addex Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
GENEVA, V8, CH HQ
2002 Founded
21 Employees
Public company Type
ADXN · NYSE Ticker
Company details
- Status
- Public
- HQ
- GENEVA, V8, CH
- Founded
- 2002
- Employees
- 21
- Programs
- 6
- Drugs
- 3
- Patents
- 40
Addex Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Addex Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Addex Therapeutics in public FDA and regional records.
-
Development asset linked to Addex Therapeutics in public FDA and regional records.